Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

709 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
Dietrich D, Hasinger O, Bañez LL, Sun L, van Leenders GJ, Wheeler TM, Bangma CH, Wernert N, Perner S, Freedland SJ, Corman JM, Ittmann MM, Lark AL, Madden JF, Hartmann A, Schatz P, Kristiansen G. Dietrich D, et al. J Mol Diagn. 2013 Mar;15(2):270-9. doi: 10.1016/j.jmoldx.2012.11.002. Epub 2012 Dec 22. J Mol Diagn. 2013. PMID: 23266319 Free PMC article.
Nucleic acid-based tissue biomarkers of urologic malignancies.
Dietrich D, Meller S, Uhl B, Ralla B, Stephan C, Jung K, Ellinger J, Kristiansen G. Dietrich D, et al. Crit Rev Clin Lab Sci. 2014 Aug;51(4):173-99. doi: 10.3109/10408363.2014.906130. Epub 2014 May 30. Crit Rev Clin Lab Sci. 2014. PMID: 24878394 Review.
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, Majores M, Stein J, Uhl B, Müller S, Ellinger J, Stephan C, Jung K, Brossart P, Kristiansen G. Gevensleben H, et al. Among authors: dietrich d. Clin Cancer Res. 2016 Apr 15;22(8):1969-77. doi: 10.1158/1078-0432.CCR-15-2042. Epub 2015 Nov 16. Clin Cancer Res. 2016. PMID: 26573597
CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M, Kristiansen G, Dietrich D. Meller S, et al. Among authors: dietrich j, dietrich d. Epigenetics. 2016 Dec;11(12):871-880. doi: 10.1080/15592294.2016.1241931. Epub 2016 Sep 30. Epigenetics. 2016. PMID: 27689475 Free PMC article.
PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.
Holmes EE, Goltz D, Sailer V, Jung M, Meller S, Uhl B, Dietrich J, Röhler M, Ellinger J, Kristiansen G, Dietrich D. Holmes EE, et al. Among authors: dietrich j, dietrich d. Clin Epigenetics. 2016 Sep 26;8:104. doi: 10.1186/s13148-016-0270-x. eCollection 2016. Clin Epigenetics. 2016. PMID: 27708722 Free PMC article.
709 results